Veterinary

 

 

With the animal vaccines market predicted to be worth $8.6 billion by 2018, can you really afford not to be a core service provider for these manufacturers? An increased focus on zoonotic infectious diseases and more attention towards the economic impact of disease in livestock of economic importance, make it clear why veterinary vaccines are coming into the limelight. This event will provide a platform for you to showcase how you are moving veterinary vaccine development methods forward, from technology to regulation and manufacture.

 

DOWNLOAD DRAFT AGENDA

 

2018 AGENDA

 

Veterinary, Wednesday 4 April 2018

One Health

Dr Cyril G Gay
Veterinary
09:10

One health zoonotic disease prioritization

  • Overview of recent efforts to prioritize zoonotic diseases
  •  Rationalising the need for vaccines, and identifying the vaccine profiles required
Professor Klaus Osterrieder
Veterinary
09:40

Vectored herpesvirus vaccines and novel approaches, for their attenuation and continued efficacy

Dr Mahesh Kumar
Veterinary
10:10

Rational Vaccine Design - Examples in Animal Heath

  • When does it make sense?
  • Speed to market vs better vaccines
10:40

Networking coffee break

Immune Enhancers & Vaccine Technology

Dr Robert Zolynas
Veterinary
11:40

Immunomodulators: Rationale for targeting the innate immune response when vaccines aren’t effective

  • Role of innate immunity
  • Immunostimulants as preventative and therapeutic agents
  • Recent developments in veterinary immunomodulators
Dr Xiaoping Zhu
Veterinary
12:10

Harnessing innate and adaptive immunity for mucosal vaccine development

Dr Jeffrey Ulmer
Veterinary
12:40

Self-amplifying RNA technology

1:10

Networking Lunch & Poster Session

Delivery and Manufacturing

Dr Darrel Styles
Veterinary
3:40

The role of veterinary vaccines in the emergency management of a foreign animal disease outbreak

4:10

Networking coffee break

Professor Thomas Geisbert
Veterinary
4:40

The need for a Nipah virus (NiV) vaccine - What are the challenges and why now?

  • Current platform review of soluble glycoprotein vaccines and virus vector platforms
  • Exact correlates of protection against NiV have not been completely defined
  • Sporadic nature of NiV outbreaks makes large scale Phase III clinical trials difficult to plan - how will we overcome this?
Dr Joan Lunney
Veterinary
5:10

Using genomics to probe for superior porcine reproductive and respiratory syndrome (PRRS) vaccine and viral infection responses

  • Impact of genomic resistance
  • Role of innate immunity
  • Targeted gene expression analyses
Dr Rhonda LaFleur
Veterinary
5:40

Nobivac® canine flu bivalent vaccine

  • Merck Animal Health’s response to CIV H3N2 outbreak in Chicago
  • CIV H3N2 infection in dogs
  • First vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8
  • Efficacy study results
  • Next steps
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 02/Apr/18 21:25

Veterinary, Thursday 5 April 2018

The role of vaccines in preventing AMR

Kemal Karaca
Veterinary
09:10

Role of vaccines in preventing further AMR - The big push

  • What are the incentives for industry?
  • Proposed diseases where development or improvement of vaccines would have a high impact on antibiotic use
  • Creating global vaccine research networks to pull resources and expertise to address gaps for priority diseases
Dr Andrew Potter
Veterinary
09:40

Advancements made in bacterial vaccines

  • Technologies for identification of antigens
  • Novel vaccine formulations
Dr Stéphane Lemiere
Veterinary
10:10

How early stage vaccine application aids decrease in the use of antibiotics, either for preventive or curative purposes in poultry

  • Benefits of early control in immunosuppressive poultry diseases
  • Application of vaccines at early stages of development, for example day 18 of age embryos for in ovo, or day old at hatch  
10:40

Networking coffee break

Panel discussion
Veterinary
11:30

Panel:Alternatives to Antibiotics: Issues and opportunities from funders’ perspective

  • How to incentivise vet pharma companies to produce new veterinary products to reduce AMR resistance
  • Marketing the science and the costs associated with this
  • Statement of societal goals that the funding entity would like to accomplish
  • Political feasibility of incentive mechanisms (e.g., is a program that gives money to large pharma companies likely to be accepted by legislators?)
  • Economics of incentive mechanisms (e.g., which incentive ‘lever’ can be pushed for maximal effect?  What would unintended consequences of such incentives be?)
12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

Dr Angela Shen
1:40

Report on U.S. vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development

  • A combined effort from HHS, NIH, CDC, FDA, BARDA to promote innovation in the development of vaccines that minimize the burden of infectious disease
  • What is the optimal process to determine which vaccines would be beneficial to public health and how information on such vaccines is disseminated to key stakeholders
  • Identifying whether obstacles exist that inhibit the development of beneficial vaccines
  • Recommendations on how best to promote and incentivize vaccine innovation and development
Dr Jeffrey Stoddard
2:10

Zoster vaccine recombinant, adjuvanted: A journey from research to approval

  • Non-live, recombinant vaccine to help prevent herpes zoster (shingles), combining glycoprotein E with an adjuvant system, AS01
  • Sharing positive results from Phase III revaccination study 
Dr Walter A Orenstein
2:40

With polio eradication succeeding, should measles eradication come next?

  • Changing the perception from polio: Focusing on measles elimination to build our overall immunization program
  • Using a “diagonal” approach when dealing with highly contagious preventable diseases like measles
  • Surveillance -  a weakness in our system?
  • Cost of controlling outbreaks and the consequences
Dr Paul Offit
3:10

Vaccine hesitancy: How to respond to the media to advance better health

  • Challenges to communicating science through the opaque prism of the media
  • How certain cultural biases can influence the perception of science 
3:40

3:40 Chair closing remarks and end of congress

last published: 02/Apr/18 21:25

 

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071